Unlocking The Potential of ZDHHC9: A Protein of Interest for Drug Targets and Biomarkers

Target Name: ZDHHC9

NCBI ID: G51114

ZDHHC9

Unlocking The Potential of ZDHHC9: A Protein of Interest for Drug Targets and Biomarkers

ZDHHC9 (Mrxsr) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of cytoplasmic proteins, which are involved in various cellular processes in the cell. ZDHHC9 is of particular interest as a potential drug target or biomarker due to its unique structure and expression pattern in different tissues.

The ZDHHC9 protein is composed of 254 amino acid residues and has a molecular weight of 31.1 kDa. It has a characteristic Rossmann-fold structure, which is a type of hydrogen-bonded alpha-helices that are commonly found in proteins that play important roles in various cellular processes. The Rossmann-fold is responsible for the protein's stability and stability, as well as its ability to interact with other proteins.

ZDHHC9 is expressed in a variety of tissues, including the brain, heart, and kidneys, and has been shown to be involved in various cellular processes. For example, it has been shown to be involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. ZDHHC9 has also been shown to be involved in the regulation of cell signaling pathways, which are the processes by which cells communicate with each other to perform various tasks.

In addition to its involvement in cellular processes, ZDHHC9 is also of interest as a potential drug target or biomarker due to its unique structure and expression pattern in different tissues. Unlike many other proteins, ZDHHC9 is not expressed in all tissues of the body, which could make it an attractive target for drugs that are designed to selectively target specific tissues. Additionally, the fact that ZDHHC9 is only expressed in certain tissues raises the possibility that drugs that target this protein may have unique effects in different tissues compared to drugs that target other proteins.

The structure and function of ZDHHC9 also make it an attractive candidate for biomarkers. By using techniques such as mass spectrometry, researchers have been able to identify unique features of ZDHHC9 that are specific to certain tissues. For example, mass spectrometry has been used to identify ZDHHC9 specificities in the brain, heart, and kidneys. These findings suggest that ZDHHC9 may be a unique biomarker for use in drug trials, as it is likely to have specific effects in different tissues compared to other proteins.

In conclusion, ZDHHC9 is a protein that is of particular interest as a potential drug target or biomarker due to its unique structure and expression pattern in different tissues. Its characteristic Rossmann-fold structure and its involvement in various cellular processes make it an attractive candidate for drug targeting, while its expression in only certain tissues also raises the possibility of unique effects in different tissues. Further research is needed to fully understand the role of ZDHHC9 as a drug target or biomarker.

Protein Name: Zinc Finger DHHC-type Palmitoyltransferase 9

Functions: Palmitoyltransferase that could catalyze the addition of palmitate onto various protein substrates (Probable). The ZDHHC9-GOLGA7 complex is a palmitoyltransferase specific for HRAS and NRAS (PubMed:16000296). May have a palmitoyltransferase activity toward the beta-2 adrenergic receptor/ADRB2 and therefore regulate G protein-coupled receptor signaling (PubMed:27481942)

The "ZDHHC9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZDHHC9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets